• Price (EUR)31.26
  • Today's Change0.71 / 2.32%
  • Shares traded121.00
  • 1 Year change-8.61%
  • Beta--
Data delayed at least 15 minutes, as of Mar 24 2023 20:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.

  • Revenue in USD (TTM)4.45bn
  • Net income in USD-131.00m
  • Incorporated2013
  • Employees8.90k
  • Location
    Perrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
  • Phone+353 17094000
  • Websitehttps://www.perrigo.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRGO:NYQ since
Nestle SA-Gateway Infant Formula Plant,Eau Claire, WisconsinDeal completed01 Nov 202201 Nov 2022Deal completed-15.96%170.00m
Data delayed at least 15 minutes, as of Mar 24 2023 20:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.